

CELZ

FLOAT SQUEEZE

biotech

low-float

premarket-movers

dilution-watch

patent-catalyst

NASDAQ

CELZ Rips Premarket on Patent Headline — But Wednesday's Tape Moved First, and the Shelf Is Freshly Loaded

August 6, 2026 — 8:52 AM EDT · Report #101 · Free Equity Reports Research

◆ DESK TAKE

Patent headline after Wednesday August 5's close sparked a 33%+ after-hours pop that premarket has extended past 60% — on a sub-5M float that's rotated many times over already this morning. Dilution read is live, not clean: S-3 shelf effective July 31, 424B3 filed August 3, so registered supply can hit any strength. Watch the ~\$1.37 premarket high as resistance and \$1.00 as support into the open.


DATA BOX

Price	\$1.10
Change	+64.47%
Volume	76.47M
Float	4.70M
Mkt cap	\$7.14M

MECHANICS

Roughly 6.5M shares outstanding with a sub-5M float. An S-3 shelf filed July 24, 2026 went effective July 31 with a 424B3 prospectus filed August 3 — active registered supply. Prior capital activity includes June 30 warrant-exercise agreements for \$4.5M gross and an October 2025 warrant inducement deal; Q1 2026 cash was \$5.7M against roughly \$1.3M quarterly operating burn.

CELZ — PRIOR SESSION → REPORT TIME



DATA BOX — MACHINE-VERIFIED

Data Box — CELZ · as of 8:50 AM ET, 2026-08-06 · Pre-market session

METRIC	VALUE
Price	\$1.10
Previous close	\$0.67
Change	+64.47%
Volume (premarket)	76.47M
Float	4.70M
Shares outstanding	6.49M
Market cap	\$7.14M
52-week range	\$0.62 - \$6.25
Avg daily volume (20d)	2.37M
Relative volume	N/A (premarket)

All figures machine-sourced from market data APIs at publication time.

Written 8:50 AM ET, Thursday August 6, before the open. The tape actually broke character a day before the headline did. CELZ spent late July and early August drifting near its 52-week low on sleepy volume — then Wednesday

August 5 traded a monster session, hundreds of times its recent daily turnover, and still closed almost exactly where it opened. Flat close, enormous churn. That combination is worth studying, because it's often what accumulation into a catalyst looks like.

Then the catalyst showed up. Patent news triggered a 33%+ after-hours surge in CELZ Wednesday evening, and premarket this morning has extended the move well past that — the stock is up more than 60% from Wednesday's close, and premarket volume alone has rotated the float many times over.

What the business actually is

Creative Medical is a clinical-stage regenerative medicine shop. The story centers on CELZ-201, or olastrocel, an allogeneic perinatal tissue-derived cell therapy in the FDA-cleared ADAPT trial for chronic lower back pain, plus platform extensions like Ultrasome for knee osteoarthritis. The IP drumbeat is real and constant — two U.S. patents issued in Q3 2025 (expiring 2042–2043) and more than 60 patents and pending applications in the portfolio. A July mid-year update flagged statistically significant 180-day improvements in chronic lower back pain for olastrocel with an FDA-cleared ADAPT expansion, and a 93% responder rate in an osteoarthritis pilot for Ultrasome.

The mechanics lesson — why the float matters more than the patent

Here's the pattern to learn. A sub-5M float means any real demand shock produces violent price discovery — there simply isn't enough stock to go around, so a 33% after-hours pop compounds into a 60%+ premarket gap.

But the same structure cuts the other way, because the dilution machinery is armed. Sequence the filings: an S-3 shelf filed July 24, effective July 31, and a 424B3 prospectus on August 3 — two days before this move. When a shelf goes effective right before a spike, the company can legally sell into your rally. History says they will: CELZ filed in late June to sell shares in a public offering, then rallied hard after withdrawing those plans, and on June 30 announced warrant-exercise agreements for \$4.5 million gross proceeds. An October 2025 warrant inducement deal was followed by a -32.7% session. Balance-sheet context: Q1 2026 showed a \$1.4 million net loss with \$5.7 million in cash after burning \$1.3 million in operating cash. They need the shelf. One more structural note: the company pays for investor-awareness services — paid promotion often amplifies moves like this one.

How it trades from here

The premarket bracket is your map. Resistance sits at the roughly \$1.35–1.40 premarket high zone; a break-and-hold above it on the open, with the tape staying over premarket VWAP (low \$1.10s), says buyers still control the supply. Lose the \$1.00 round number and the air pocket back toward the 60s reopens fast. Watch for a pricing prospectus or 8-K this morning — shelf paper hitting the tape is the single event most likely to cap this. LULD halts are near-certain on a float this thin, so size positions assuming you can't exit at will. Second act depends on a follow-on release; this company layers PRs, and the June episode shows these moves can run multiple sessions when supply stays off the tape.

Not investment advice — do your own research and size for the volatility.

MECHANICS BOX — THE STRUCTURAL READ

- Shares outstanding: 6.49M · Float: 4.70M
- Dilution-relevant SEC filings (30d): 424B3 (2026-08-03), S-3 (2026-07-24)

- Splits: 1-for-10 reverse (2023-06-12), 1-for-500 reverse (2021-11-10), 1-for-150 reverse (2020-02-03)
- Roughly 6.5M shares outstanding with a sub-5M float. An S-3 shelf filed July 24, 2026 went effective July 31 with a 424B3 prospectus filed August 3 — active registered supply. Prior capital activity includes June 30 warrant-exercise agreements for \$4.5M gross and an October 2025 warrant inducement deal; Q1 2026 cash was \$5.7M against roughly \$1.3M quarterly operating burn.

The Setup: This is a [Float Squeeze](#) play — read the pattern guide to learn how these setups typically unfold.

This report is for informational purposes only and does not constitute investment advice. Always conduct your own due diligence before making any investment decision.